OmniAb (NASDAQ:OABI) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Key Points

• OmniAb beat quarterly expectations: The company reported an adjusted loss of $0.05 per share versus the $0.12 consensus loss, while revenue reached $13.41 million compared with estimates of $4.69 million.
• Operating performance improved: Second-quarter revenue increased to $13.4 million from $3.9 million year over year, driven mainly by partner milestones, and net loss narrowed to $5.9 million from $15.9 million.
• Guidance and pipeline advanced, but risks remain: OmniAb raised and narrowed 2026 revenue guidance to $32 million–$36 million and reported 425 active programs, though revenue depends heavily on milestone timing and analysts maintain a “Hold” consensus rating.

OmniAb (NASDAQ:OABI - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.07, FiscalAI reports. The company had revenue of $13.41 million for the quarter, compared to analyst estimates of $4.69 million. OmniAb had a negative return on equity of 16.45% and a negative net margin of 115.12%.

Here are the key takeaways from OmniAb's conference call:

• Q2 revenue rose to $13.4 million from $3.9 million year over year, driven primarily by partner milestone revenue; net loss narrowed to $5.9 million from $15.9 million.
• OmniAb raised and narrowed its 2026 guidance, now forecasting revenue of $32 million–$36 million, GAAP operating expenses of $84 million–$88 million, and year-end cash of $37 million–$41 million.
• The partnered pipeline continued to advance, with 425 active programs, 34 active clinical programs or approved products, four new clinical entrants in 2026, and approximately $340 million in remaining potential milestones tied to clinical-stage programs.
• The company sold two xPloration instruments during Q2, bringing the field total to four, and said the platform could generate recurring revenue from consumables, software, maintenance, and services.
• Revenue remains heavily dependent on milestone timing and was front-loaded in the first half of 2026; despite improved cash use, OmniAb expects to end the year with less cash than the $52 million held at the end of Q2.

OmniAb Trading Up 37.5%

Shares of NASDAQ OABI traded up $0.84 during trading on Friday, reaching $3.08. 2,672,840 shares of the stock were exchanged, compared to its average volume of 402,782. The business's 50-day moving average price is $2.26 and its 200 day moving average price is $1.96. OmniAb has a twelve month low of $1.30 and a twelve month high of $3.12.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC increased its holdings in OmniAb by 114.2% during the 3rd quarter. Squarepoint Ops LLC now owns 35,431 shares of the company's stock worth $57,000 after purchasing an additional 18,890 shares during the last quarter. Sei Investments Co. raised its position in shares of OmniAb by 32.6% in the 3rd quarter. Sei Investments Co. now owns 81,045 shares of the company's stock valued at $130,000 after purchasing an additional 19,919 shares in the last quarter. Bridgeway Capital Management LLC purchased a new position in shares of OmniAb during the 2nd quarter valued at approximately $94,000. Brevan Howard Capital Management LP purchased a new position in shares of OmniAb during the 2nd quarter valued at approximately $94,000. Finally, The Manufacturers Life Insurance Company grew its position in shares of OmniAb by 20.5% during the second quarter. The Manufacturers Life Insurance Company now owns 44,809 shares of the company's stock worth $78,000 after buying an additional 7,624 shares in the last quarter. Hedge funds and other institutional investors own 72.08% of the company's stock.

Analyst Ratings Changes

Separately, Weiss Ratings lowered OmniAb from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, OmniAb has an average rating of "Hold".

About OmniAb

OmniAb, Inc NASDAQ: OABI operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source